Depomed (DEPO) Misses Q2 EPS by 1c, Trims FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
DepoMed Inc (DEPO) PT Lowered to $9 at Piper Jaffray
August 8, 2017 8:23 AM EDTPiper Jaffray lowered its price target on DepoMed Inc (NASDAQ: DEPO) to $9.00 (from $10.00) while maintaining a Neutral rating following Q2 results and another downward guide.
"Notably, DEPO cut its 2017 revenue and EBITDA guidance ranges once again, driven in part by continued headwinds... More
